Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8(+) T cells

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F86652036%3A_____%2F17%3A00508201" target="_blank" >RIV/86652036:_____/17:00508201 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.tandfonline.com/doi/full/10.1080/2162402X.2017.1318234" target="_blank" >https://www.tandfonline.com/doi/full/10.1080/2162402X.2017.1318234</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/2162402X.2017.1318234" target="_blank" >10.1080/2162402X.2017.1318234</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8(+) T cells

Popis výsledku v původním jazyce

An important question is how chemotherapy may (re-) activate tumor-specific immunity. In this study, we provide a phenotypic, functional and genomic analysis of tumor-specific CD8(+) T cells in tumor (P815)-bearing mice, treated or not with cyclophosphamide. Our data show that chemotherapy favors the development of effector-type lymphocytes in tumor bed, characterized by higher KLRG-1 expression, lower PD-1 expression and increased cytotoxicity. This suggests re- engagement of T lymphocytes into the effector program. IFN-I appears involved in this remodeling. Our findings provide some insight into how cyclophosphamide regulates the amplitude and quality of tumor-specific immune responses.

Název v anglickém jazyce

Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8(+) T cells

Popis výsledku anglicky

An important question is how chemotherapy may (re-) activate tumor-specific immunity. In this study, we provide a phenotypic, functional and genomic analysis of tumor-specific CD8(+) T cells in tumor (P815)-bearing mice, treated or not with cyclophosphamide. Our data show that chemotherapy favors the development of effector-type lymphocytes in tumor bed, characterized by higher KLRG-1 expression, lower PD-1 expression and increased cytotoxicity. This suggests re- engagement of T lymphocytes into the effector program. IFN-I appears involved in this remodeling. Our findings provide some insight into how cyclophosphamide regulates the amplitude and quality of tumor-specific immune responses.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Oncoimmunology

ISSN

2162-402X

e-ISSN

—

Svazek periodika

6

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

e1318234

Kód UT WoS článku

000408961700005

EID výsledku v databázi Scopus

—